Nabriva Therapeutics Plc

-0.03 (-3.81%)
Earnings Announcements

Nabriva Therapeutics Posts Q3 Revenue Of $8.9 Million

Published: 11/09/2021 21:58 GMT
Nabriva Therapeutics Plc (NBRV) - Nabriva Therapeutics Reports Third Quarter 2021 Financial Results and Provides a Corporate Update.
Q3 Revenue $8.9 Million.
Cash Runway Extended to Substantially Through Q2 2022.
Qtrly Revenues of $8.9 Million Increased 8% Sequentially Versus Q2 2021.
Revenue is expected to be $9.85 Million
Adjusted EPS is expected to be -$0.21

Next Quarter Revenue Guidance is expected to be $11.6 Million
Next Quarter EPS Guidance is expected to be -$0.20

More details on our Analysts Page.